FREDERICK, Md., May 13, 2009 — SAIC-Frederick Inc., a wholly owned subsidiary of Science Applications International Corporation (SAIC) [NYSE: SAI], and Sensor Technologies Inc. of Shrewsbury, Mass., have signed a collaboration agreement to begin integrated studies of complex protein interactions involved in cancer and other diseases.

The agreement is part of the National Cancer Institute’s Advanced Technology Partnerships Initiative, which aims to further NCI’s mission by speeding the translation of research discoveries into new treatments for cancer and AIDS. SAIC-Frederick, as prime contractor for the National Cancer Institute at Frederick, is facilitating these partnerships for the government.

The collaboration will involve proteomics and imaging studies to advance the understanding of complex structural interactions and binding kinetics of proteins in cells and in cancer disease processes.

The Optical Microscopy and Analysis Laboratory (OMAL) and Protein Chemistry Laboratory (PCL) at SAIC-Frederick, together with Sensor Technologies, will begin integrated studies to assess the dynamics of fluorescence-tagged molecules utilizing Sensor Technologies’ newly launched Fluorescence Correlation Spectroscopy (FCS) platform—“QuantumXpert™.”

Studies will also include integration with in vivo microscopy techniques in OMAL with the goal of developing dynamic, biomolecular models that are both physical and performed by computer simulation. Sensor has redefined FCS, creating the first portable, three-channel FCS spectrometer, enabling studies of molecular complexing and interaction at single-molecule levels. The QuantumXpert™ and Sensor’s revolutionary FCSXpert™ software introduce this important single molecule technique into the laboratories of biochemistry and cell and molecular biology in an easy-to-use format.

Applications of this technology have the potential to provide insights that could accelerate the development of new treatments. By integrating this enabling platform with in vivo microscopy techniques, the research teams also seek to advance the field of computer simulation modeling in cancer research and development.

“SAIC-Frederick is very pleased to be collaborating with the science and technology experts at Sensor Technologies. We believe our cooperative efforts to study and integrate leading biomolecular analysis and imaging technologies will result in new insights and analytical approaches to tumor cell biology and function,” said Dr. Stephen Lockett, head of OMAL at SAIC-Frederick.

“Sensor Technologies welcomes the opportunity to bring the detection and measurement capabilities of its FCS platform to bear on the large challenges inherent in understanding the cell biology of cancer and AIDS,” said Dr. David E. Wolf, chief science officer for Sensor Technologies.

About SAIC-Frederick

SAIC-Frederick Inc. is the prime contractor for NCI’s research and development center in Frederick, Md. This is a national laboratory dedicated to rapidly translating basic research into new technologies for diagnosing, treating, and preventing cancer and AIDS. SAIC-Frederick conducts basic research and maintains a full suite of advanced technologies in areas such as nanotechnology, genomics and imaging. The company operates the federal government’s only drug and vaccine manufacturing facilities; operates the high-performance Advanced Biomedical Computing Center; and supports more than 300 clinical trials for patients in the United States and around the world. SAIC-Frederick is a wholly owned subsidiary of SAIC, a Fortune 500® company (NYSE: SAI).

Information about NCI’s Advanced Technology Partnerships Initiative can be found at https://www.ncifcrf.gov/atpi/

About Sensor Technologies

Sensor Technologies Inc. is a privately-held Massachusetts corporation. Sensor’s core expertise lies in the use of fluorescence-based approaches for detecting and measuring with extreme precision and accuracy. Sensor developed and introduced its fluorescence correlation spectroscopy (FCS) system, the QuantumXpert™, to bring the powerful single-molecule measurement capabilities of FCS to a much broader scientific marketplace. The key features of this new implementation of FCS are its accuracy, ease of use, small size, and value proposition. Systems biology advances are placing an increasingly higher premium upon data that illuminates binding and complexing at the level of single molecules. Sensor’s QuantumXpert™ offers the first bench-top fluorescence correlation spectrometer to address this scientific challenge directly.

Information about Sensor’s FCS Technology Platform can be found at https://www.fcsxpert.com